Hope Or Hype? Pitney Bowes Inc. (PBI), Novavax, Inc. (NVAX)

Pitney Bowes Inc. (NYSE:PBI) has its shares plummet by -41.59% or $3.46 from its all-time high of $8.32, with PBI attaining that price back on February 22, 2019. The drop in the price of the shares saw it stand at $4.86 per share. PBI has been trading at a low of $3.14 over the past one year but it surged by 54.78% or $1.72 to reach the $4.86 mark. Following the massive rise in stock price, PBI received more attention from investors and analysts. On Monday, the stock dipped by -0.21%, which caused investors and analysts to worry about it. Following the plunge in price, the PBI beta stands at 2, implying that its volatility level has gone up by -1 ahead of the general market. A look at the stock’s 200-day moving average shows that it is -2.01% below while its 50-day moving average shows that it is currently 3.42% above. Compared to 4.32% average daily volatility of past month, the stock’s average volatility for this week has decreased by -0.94 as the volatility level currently stands at 3.38%.

Over the past seven days, the stock has witnessed a price surge by 0.62%. This massive rise in stock price has caught the attention of both investors and market traders. The stock has performed poorly over the past 52 weeks, dropping by -31.45% during that time frame and is now down by -17.77% since this point this year. PBI has fell by -2.99% over the past 30 days, with its equity price gaining% of its value over the past ninety days. These figures add up to see the stock record a growth of 9.95% over the past six months.

Market analysts from research firms still remain bullish about the short-term performance of PBI. Most of them are of the view that the stock would be able to reach $5.5 over the next 12 months. If that happens, then the stock would witness a 13.17% rise in its price and that would see the stock’s market cap hit an astonishing $936 Million. Analysts view this stock as a bearish at the moment as its average rating is 2.6. According to Reuters, many of the 2 analysts covering the stock at the moment believe it is a Buy. 1 of them rated PBI as a Hold while 1 of them either rated it as a Buy or a Strong Buy. However, 0 of them advised investors to sell the stock if they have it or shouldn’t buy it if they don’t possess any.

The stock’s technical analysis reveals that its 14-day Relative Strength Index (RSI) is currently in a neutral position as it was able to attain 55.9 points. The trading volume now standing at 2652599 shares. The increase of 262599 shares in trading volume shows that traders and investors have shown more interest in the stock over the past few weeks. During that trading session, the average trading volume of PBI was 2390000 shares, which is more than 1.11 times higher than its usual trading volume.

Novavax, Inc. has seen its stock (NASDAQ:NVAX) plunge by $-0.19 or -4.37% to currently trade at $4.16. This fall in the price of the stock has seen it establish a strong support at $4.06 a share. If the stock price is to drop below that support level, then it would be followed by a bearish trend. A slip below $3.95 would be bad for NVAX as it would mean that the stock has lost 5.05% of its value. The stock going in the opposite direction and breaking past the resistance point to reach $4.37 would see it surge even higher. NVAX would attempt to surge past the upward resistance point which is set at $4.57 a share. NVAX has an average volatility of 7.99% over the past 30 days, while it has gained 14.9% of its value compared to its 52-weeks low point which stands at $3.54 on Nov 21, 2019. In the same breath, NVAX has lost 0% compared to its 52-weeks high point which currently stands at $4.16 a share reached on Dec 13, 2018.

Analysts have set a 1-year price target for this stock, with most of them expecting it to reach $13.75/share over the next 12 months. If that happens, then NVAX would witness a 230.53% rise from its current price. The price of the stock has been moving between $4.16 and $4.47. Not all analysts believe it would hit that target though, as some of them expect it to trade lower, as low as $6 per share. In the same breath, one analyst believes that the stock is set to soar even higher than expected, as the price target was set at $27.5.

The stock has an average rating of 2.3 which means that it has been rated as a Hold by most analysts. The stock is being covered by 8 analysts who gave a consensus recommendation of 2.3 which implies that it is currently in a neutral situation. Reuters looked into analysts covering Novavax, Inc., and 2 of them believe that the stock is a Hold at the moment. 6 of the analysts rated it as a Buy or a Strong Buy while the remaining analysts (1) rated it as a sell at the moment.